AIDS Market Is Expected To Grow During the Forecast Period (2019-2032), DelveInsight

A detailed review of the historical and forecasted AIDS market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global AIDS market. An all-inclusive account of both the current and emerging therapies for AIDS, along with the assessment of new therapies, will have an impact on the current treatment landscape.

AIDS: An Overview
Acquired Immuno Deficiency Syndrome (AIDS) is the most severe stage of HIV infection when a person's CD4 cell count drops below 200 cells/mm and the person's immune system is no longer able to control viral infection. AIDS is caused by Human Immunodeficiency Virus (HIV). It is transmitted sexually, via blood transfusions, sharing intravenous needles, and from the mother to a child during the birth process and breastfeeding. HIV disease has distinct phases: viral transmission, acute seroconversion, acute retroviral syndrome, recovery and seroconversion, asymptomatic chronic infection, and symptomatic HIV infection or acquired immunodeficiency syndrome (AIDS.)
Discover more information about the report- https://www.delveinsight.com/sample-request/acquired-immunodeficiency-syndrome-aids-market

Key highlights of the AIDS Market Report
• From 2015 to 2019, new infections among young g#y and bisexual men (ages 13-24) dropped 33% overall, with declines in young men of all races, but African Americans and Hispanics/Latinos continue to be severely and disproportionately affected.
• At year-end 2019, an estimated 2 million people in the United States aged 13 and older had HIV. According to another CDC report, of the estimated 1.2 million people with HIV (diagnosed and undiagnosed) in 2019, about 65.9% received some HIV care, 50.1% were retained in care, and 56.8% were virally suppressed or undetectable.
• G@y, bisexual and other men who have sex with men (MSM) are the population most affected by HIV in the U.S. MSM accounted for 69% of new HIV diagnoses in the United States.

AIDS Epidemiology Segmentation in the 7MM
• Prevalence of HIV in "AT RISK" groups
• Total AIDS Prevalence
• Total AIDS Prevalence
• Total AIDS Incidence

AIDS Market Forecast
The Acquired ImmunoDefeiciency Virus (AIDS) market is forecasted to grow from XX in 2018 to XX in 2030. The increase in disease burden prevalence in almost all 7MM, rise in general awareness, steady increase in penetration of diagnostic techniques, a robust pipeline of HIV Vaccines are the major growth drivers of HIV/AIDS Market. However, huge investments in R&D and strict regulatory norms and long timelines required to develop vaccines increases the ROI risk involved, which hampers the HIV market. Growing awareness (Role of NGOs) and rise in PPP models in implementation are glittering opportunities in HIV market.

AIDS Treatment Market
Symptomatic Treatment for AIDS consists of, Antiretroviral (ART) drugs (major therapy to decrease viral load), and other treatments for specific clinical manifestations. HIV Drugs market is classified into many types based on Type of medications: Multi-class Combination drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors, and HIV integrase strand transfer inhibitors.

AIDS Market Insights
With a worldwide disease burden of 35Mn, there is a gigantic need for Prevention and Cure for HIV infections. Many pharmaceutical and Bio-tech companies are venturing with novel therapies to revolutionize the AIDS Market in the forecast period.

Request a Sample Copy of the Report- https://www.delveinsight.com/sample-request/acquired-immunodeficiency-syndrome-aids-market

AIDS Market Size
The market size shall increase owing to the launch of upcoming therapies, increasing awareness and diagnosis of patient populations. Market size of Acquired ImmunoDeficiency Syndrome (AIDS) in the 7MM was USD XX million in 2018 and is estimated to increase to USD XX million by 2030.

AIDS Emerging Therapy Assessment
There is an increasing need for updated HIV drugs that can treat prevalent patient population as it faces challenges like Multi-Drug Resistance, declining-response to ART (Anti-retroviral therapy). This poses a great opportunity to exploit, considering significant disease burden in 7MM. AIDS Market looks robust with a long pipeline of both drugs & vaccines candidates.

AIDS Market Companies & Therapies
• Cabotegravir: ViiV Healthcare
• VAC89220: Johnson and Johnson
• HTI Immunogen Sequence: Aelix Therapeutics
• GS-5423 and GS-2872: Gilead, and Several Others

Explore information about the report- https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market

Table of Content
1. Key Insights
2. Executive Summary of AIDS
3. Competitive Intelligence Analysis for AIDS
4. AIDS: Market Overview at a Glance
5. AIDS: Disease Background and Overview
6. Patient Journey
7. AIDS Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. AIDS Unmet Needs
10. Key Endpoints of AIDS Treatment
11. AIDS Marketed Products
12. AIDS Emerging Therapies
13. AIDS: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of AIDS
17. KOL Views
18. AIDS Market Drivers
19. AIDS Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with our Business Expert @ https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.